Long-Term Follow-up Protocol
Condition(s):Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis BullosaLast Updated:June 8, 2021Recruiting
Hide Studies Not Open or Pending
Condition(s):Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis BullosaLast Updated:June 8, 2021Recruiting
Condition(s):Epidermolysis BullosaLast Updated:March 25, 2015Completed
Condition(s):Epidermolysis Bullosa DystrophicaLast Updated:March 13, 2024Active, not recruiting
Condition(s):Epidermolysis Bullosa Dystrophica; Squamous Cell CarcinomaLast Updated:November 27, 2023Recruiting
Condition(s):Pain, Neuropathic; Itch; Epidermolysis BullosaLast Updated:February 12, 2024Completed
Condition(s):Dystrophic Epidermolysis Bullosa; DEB – Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis BullosaLast Updated:August 18, 2023Completed
Condition(s):RDEBLast Updated:February 3, 2023Enrolling by invitation
Condition(s):Epidermolysis Bullosa DystrophicaLast Updated:February 17, 2023Active, not recruiting
Condition(s):Epidermolysis Bullosa Dystrophica, Recessive; Epidermolysis Bullosa Dystrophica, DominantLast Updated:August 25, 2021Terminated
Condition(s):Epidermolysis Bullosa Dystrophica, RecessiveLast Updated:October 19, 2021Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.